ReviewHepatic medicine : evidence and research2021
The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics.
Review in Hepatic medicine : evidence and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Assessment of hepatic fibrosis in Egyptian children and adolescents with beta thalassemia major: a single center study.European journal of pediatrics · 2026Article
- Observational
- Beyond Organ-Specific Therapies: A Unified Approach to Multi-Organ Fibrosis.Drug design, development and therapy · 2026Review
- Application of artificial intelligence in hepatology.Frontiers in digital health · 2026Review
- Disease patterns and entities in adult liver consult cases highlight challenging areas in diagnostic hepatopathology practice.Virchows Archiv : an international journal of pathology · 2025Article
- New Challenges in the Study of Liver Diseases: From Molecular Pathogenesis to Therapeutic Approaches (3rd Edition).Biomedicines · 2025Article
- Diabetes and NAFLD: A Synergistic Threat to Metabolic Health.Advanced pharmaceutical bulletin · 2025Review
- CT-Based Radiomic Models in Biopsy-Proven Liver Fibrosis Staging: Direct Comparison of Segmentation Types and Organ Inclusion.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic yield and adverse events of liver biopsy in intensive-care-unit patients: a multicenter retrospective observational cohort study.Annals of intensive care · 2025Article
- Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes.Life (Basel, Switzerland) · 2025Review
- Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys.Scientific reports · 2024Article
- NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.International journal of molecular sciences · 2024Review
- Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma.Journal of translational medicine · 2024Article
- Development and validation of machine learning models for MASLD: based on multiple potential screening indicators.Frontiers in endocrinology · 2024Article
- Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study.Hepatology forum · 2024Article
- Enhancing patient outcomes: the role of clinical utility in guiding healthcare providers in curating radiology AI applications.Frontiers in digital health · 2024Article
- Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study.Infectious disease reports · 2023Article
- Fluorescence lifetime needle optical biopsy discriminates hepatocellular carcinoma.Biomedical optics express · 2022Article
- Current Status of Biomarkers and Molecular Diagnostic Tools for Rejection in Liver Transplantation: Light at the End of the Tunnel?Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histology remains essential for the diagnosis and management of many disorders affecting the liver. However, the biopsy procedure itself is associated with a low risk of harm to the patient and cost to the health services; samples may not be adequate and are subject to sampling variation. Furthermore, interpretation often depends on the skill of the pathologist. Increasingly, new techniques are becoming available that are altering the indications for liver biopsy. Many diseases of the liver can be diagnosed and managed using serological and radiological techniques; the degree of fibrosis and fat can often be assessed by serological or imaging techniques and the nature of space occupying lesions defined by serology, imaging and use of liquid biopsy. However, these techniques, too, are subject to limitations: sensitivity and specificity is not always adequate for diagnosis or management; some techniques are expensive and often also require expert interpretation. Although there may be less need for liver biopsy today, histology remains the gold standard as well as an essential tool for the diagnosis and management of many conditions, especially where there are multiple pathologies, or where a diagnosis cannot or has not been made by alternative approaches. Until less invasive techniques become more reliable and accessible, liver histology will remain a key investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.